Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 20, 2024, the submission of three international patent applications. These applications, filed under the Patent Cooperation Treaty (PCT), are in collaboration with SciSparc Ltd., a company focusing on central nervous system disorders. The patents pertain to novel combinations of classic psychedelic substances including LSD, psilocybin, DMT, and SciSparc's proprietary compound Palmitoylethanolamide (PEA). Initially filed as provisional applications with the USPTO, these submissions expand Clearmind's intellectual property portfolio, which now comprises 27 granted patents and 24 pending applications across 15 families. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the strategic move to protect their compounds in multiple countries, reinforcing their position in the psychedelic market. Clearmind, which is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, aims to develop and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, particularly targeting alcohol use disorder among other health issues.